We are also advancing OCT guided targeted laser microirradiation technology for creating models of degenerative eye diseases such as Retinitis Pigmentosa (RP) and dry age-related macular degeneration (dry-AMD) as well as for targeted delivery of therapeutic genes.
The device could be especially useful in studies involving wound healing, as we are currently lacking a tool that maps the length and the depth of skin ridges. Currently, we rely on photographs or measurements in our trials which could only provide a 2D assessment.
For Boston Scientific, an important impetus of continuous growth in the China market is to collaborate with local partners to satisfy more local patients' unmet needs through diversified innovative channels.
“I am inspired by Dr. Sanford Greenberg’s vision to end blindness and humbled to be recognized along with Prof. Jim Fujimoto and Eric Swanson for the development of optical coherence tomography, a very sensitive imaging technology widely used to detect and diagnose eye diseases...At the Casey Eye Institute, we are continuing to work on ending all preventable blindness by advancing diagnostic technologies, broadening community outreach, and providing cutting edge treatments.
Our goal was to use this uniquely large set of fundus and OCT images to develop a method which will reduce the need of expensive annotated data for algorithm training.
We will develop a novel method for the imaging and assessment of corneal elastic properties that could potentially be used for routine clinical diagnostics of different corneal diseases and treatment.
